An observational study in End Stage Renal Disease Patients, ESRD and Renal Failure, sponsored by Shimaa Salah Ali. Not yet recruiting. Open to participants aged 18 Months and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Shimaa Salah Ali · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Hemodialysis Fistula-Related Ischemic Neuropathy in End-Stage Renal Failure: An Electrophysiological Study A single study in Assiut university hospital
End-stage renal failure (ESRF) represents a major global health burden, with hemodialysis being the most common renal replacement therapy. The creation of an arteriovenous fistula (AVF) Is considered the preferred vascular access for long-term hemodialysis due to its superior patency and lower complication rates compared to grafts and catheters (1-2) Despite its advantages, AVF creation may be associated with several complications, including ischemic steal syndrome and ischemic monomelic neuropathy (IMN). Ischemic neuropathy is a rare but potentially disabling complication resulting from acute or chronic ischemia of peripheral nerves following AVF creation. Patients may present with severe pain, sensory disturbances, weakness, and functional impairment of the affected limb (3-5) Early diagnosis remains challenging because symptoms may overlap with uremic neuropathy, diabetic neuropathy, and other peripheral nerve disorders commonly encountered in ESRF patients. Electrophysiological studies, including nerve conduction studies (NCS) and electromyography (EMG), provide objective assessment of nerve dysfunction and may facilitate early diagnosis and differentiation from other neuropathic conditions Limited data are available regarding the electrophysiological characteristics of AVF-related ischemic neuropathy, particularly in ESRF populations. Therefore, a comprehensive electrophysiological evaluation may contribute to improved recognition, management, and prevention of long-term disability
Hemodialysis fistula-related ischemic neuropathy is an under-recognized complication in patients with ESRF. Delayed diagnosis may lead to irreversible neurological deficits and impaired quality of life. The electrophysiological features and associated risk factors remain insufficiently characterized in many dialysis populations
This study aims to provide a detailed electrophysiological assessment of ischemic neuropathy associated with AVF creation in ESRF patients. The findings may facilitate early diagnosis, improve clinical outcomes, and contribute to developing screening and management strategies for high-risk patients
Aim of the Work:
To evaluate electrophysiological abnormalities associated with hemodialysis fistula-related ischemic neuropathy in patients with end-stage renal failure
Patients and methods:
Type of the study: Analytical Cross-Sectional Case-Control Study Study Setting: The study will be conducted at Nephrology and Hemodialysis Unit at Assuit University hospital
Study duration: august 2026 - august 2027 Study populations: Patients diagnosed with end-stage renal failure undergoing maintenance hemodialysis through an arteriovenous fistula Group I (Cases) ESRF patients with clinical evidence of AVF-related ischemic neuropathy Group II (Controls)
Methodology A. Clinical Assessment
All participants will undergo:
Detailed medical history, Dialysis history
AVF characteristics:
Site of fistula Duration since creation Side of fistula Previous vascular interventions
Neurological examination:
Motor assessment Sensory assessment Deep tendon reflexes Muscle strength grading using MRC scale B. Laboratory Investigations Complete blood count (CBC) Serum creatinine Blood urea nitrogen (BUN) Electrolytes HbA1c (for diabetic patients) Serum albumin Calcium and phosphorus levels C. Vascular Assessment Duplex Doppler ultrasonography of AVF Assessment of arterial flow and steal phenomenon D. Electrophysiological Assessment
Nerve Conduction Studies (NCS):
Electromyography (EMG)
2,115 studies on the registry are indexed under Kidney Failure, Chronic; 276 are open to participants now.
This study's planned enrollment of 50 is below the median of 120 across 444 observational studies indexed under Kidney Failure, Chronic.
Browse Kidney Failure, Chronic studies →This is the only study on the registry with Shimaa Salah Ali as lead sponsor.
Counted across the registry records on this site, refreshed daily.
: Patients diagnosed with end-stage renal failure undergoing maintenance hemodialysis through an arteriovenous fistula Group I (Cases) ESRF patients with clinical evidence of AVF-related ischemic neuropathy Group II (Controls)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Motor Nerve Conduction Velocity
Assessed by Nerve Conduction Studies on the upper limb with the arteriovenous fistula . Measured in meters per second.
Time frame: Up to 1 year post-AVF creation
Arteriovenous Fistula Blood Flow Volume
Assessed by Duplex Doppler Ultrasound on the arteriovenous fistula. Measured in milliliters per minute.
Time frame: Up to 1 year post-AVF creation
Sensory Nerve Conduction Velocity
Assessed by Nerve Conduction Studies on the upper limb with the arteriovenous fistula . Measured in meters per second
Time frame: Up to 1 year post-AVF creation
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jan 2028, 13 months later.
Of 132 non-industry observational studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 62. This study's planned 13 months is below that.
Counting every sponsor, half of 151 studies reached it within 29 months; a quarter within 11 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.